Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168) intends to acquire Taizhou Women and Children's Hospital Co., Ltd. from Shanghai Yuxie Medical Management Co., Ltd. and Shanghai Xiehe Hospital Investment Management Co., Ltd. for approximately CNY 500 million on September 30, 2020. Within 10 working days from the effective date of this agreement, Zhejiang Shapuaisi Pharmaceutical shall pay Shanghai Yuxie Medical Management and Shanghai Xiehe Hospital Investment Management 60% of the equity transfer payment and the remaining 40% of the equity transfer price within 10 working days from the date when Taizhou Women and Children's Hospital’s 2020 annual performance special review opinion is issued. In December 31, 2019, Taizhou Women and Children's Hospital reported a total assets of CNY 200 million, total common equity of CNY 114 million, total revenues of CNY 172 million and net income of CNY 28.7 million. The transaction is approved by the board of directors of Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. in the board meeting and is subject to approval from the shareholders of Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHSE:603168) completed the acquisition of Taizhou Women and Children's Hospital Co., Ltd. from Shanghai Yuxie Medical Management Co., Ltd. and Shanghai Xiehe Hospital Investment Management Co., Ltd. on October 28, 2020.